Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€3.35

€3.35

-4.130%
-0.144
-4.130%
-
 
17.05.24 / Tradegate WKN: A2QKXS / Name: Abcellera Biologics Inc. / Stock / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Abcellera Biologics Inc. Stock

Heavy losses for Abcellera Biologics Inc. today as the stock fell by -€0.144 (-4.130%).

Pros and Cons of Abcellera Biologics Inc. in the next few years

Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
S********** s********
?
C******** o* t** e**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'

News

AbCellera Reports Q1 2024 Business Results: https://mms.businesswire.com/media/20210119006096/en/705128/5/AbCellera_Full_Colour_RGB_1.jpg
AbCellera Reports Q1 2024 Business Results


AbCellera (Nasdaq: ABCL) today announced financial results for the first quarter of 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies: https://mms.businesswire.com/media/20210119006096/en/705128/5/AbCellera_Full_Colour_RGB_1.jpg
AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies


AbCellera (Nasdaq: ABCL), Viking Global Investors (“Viking”), and ArrowMark Partners (“ArrowMark”) announced today that they have entered into a collaboration to advance new antibody drug programs

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024: https://mms.businesswire.com/media/20210119006096/en/705128/5/AbCellera_Full_Colour_RGB_1.jpg
AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024


AbCellera (Nasdaq: ABCL) today announced new data on its T-cell engager (TCE) programs at the American Association for Cancer Research (AACR) Annual Meeting 2024 at the San Diego Convention